Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
THTX 
Theratechnologies Inc. (THTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: THTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.04
1 Year Target Price $4.04
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.73% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 151.87M USD | Price to earnings Ratio - | 1Y Target Price 4.04 |
Price to earnings Ratio - | 1Y Target Price 4.04 | ||
Volume (30-day avg) 3 | Beta 0.81 | 52 Weeks Range 1.12 - 3.32 | Updated Date 09/16/2025 |
52 Weeks Range 1.12 - 3.32 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.85% | Operating Margin (TTM) -10.74% |
Management Effectiveness
Return on Assets (TTM) 7.33% | Return on Equity (TTM) -1116.86% |
Valuation
Trailing PE - | Forward PE 55.87 | Enterprise Value 185568454 | Price to Sales(TTM) 1.8 |
Enterprise Value 185568454 | Price to Sales(TTM) 1.8 | ||
Enterprise Value to Revenue 2.2 | Enterprise Value to EBITDA 76.46 | Shares Outstanding 45980000 | Shares Floating 38229167 |
Shares Outstanding 45980000 | Shares Floating 38229167 | ||
Percent Insiders 1.15 | Percent Institutions 45.49 |
Upturn AI SWOT
Theratechnologies Inc.
Company Overview
History and Background
Theratechnologies Inc. is a biopharmaceutical company founded in 1993 and headquartered in Montreal, Canada. Initially focused on HIV-related complications, it has expanded to other therapeutic areas, including oncology.
Core Business Areas
- HIV: Development and commercialization of therapies for HIV-associated complications, primarily focusing on metabolic disorders.
- Oncology: Development and commercialization of therapies for oncology-related conditions.
Leadership and Structure
The leadership team includes a CEO, CFO, and other key executives. The organizational structure is typical of a biopharmaceutical company, with departments for R&D, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- EGRIFTA (tesamorelin): EGRIFTA is a growth hormone-releasing factor analogue indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. While specific market share data fluctuates, EGRIFTA is a key player in this niche market. Competitors are companies developing therapies for metabolic disorders, although EGRIFTA is specifically targeted for HIV-associated lipodystrophy. Estimated Revenue from this product is $67M USD as of 2023
- Trogarzo (ibalizumab-uiyk): Trogarzo is a long-acting, humanized monoclonal antibody for the treatment of multi-drug resistant HIV-1 infection. The product has been approved in multiple countries. Competitors include other antiretroviral therapies for HIV, but Trogarzo is specifically for patients with limited treatment options. Estimated Revenue from this product is $71M USD as of 2023.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The markets for HIV and oncology therapies are large and growing.
Positioning
Theratechnologies is a niche player, focusing on specialized therapies for HIV and oncology. Its competitive advantage lies in its expertise in these areas and its established relationships with healthcare providers and patient advocacy groups.
Total Addressable Market (TAM)
The TAM for HIV and oncology treatments is substantial, estimated to be in the billions of dollars. Theratechnologies is positioned to capture a share of this market through its specialized therapies. Exact figure is difficult to ascertain but an approximation would be $300B USD.
Upturn SWOT Analysis
Strengths
- Specialized expertise in HIV and oncology
- Approved products with established market presence
- Strong relationships with healthcare providers
- Proprietary technology platform
Weaknesses
- Limited product pipeline
- Dependence on a few key products
- Relatively small size compared to major pharmaceutical companies
- Geographic concentration in North America.
Opportunities
- Expansion into new therapeutic areas
- Development of new formulations of existing products
- Partnerships and collaborations with other companies
- Geographic expansion into emerging markets
Threats
- Competition from larger pharmaceutical companies
- Patent expirations
- Changes in regulatory requirements
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- GILD
- BMY
- MRK
Competitive Landscape
Theratechnologies faces significant competition from larger pharmaceutical companies with greater resources. However, its specialized focus and established products provide a competitive advantage in specific niches.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: None
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the increasing adoption of EGRIFTA and Trogarzo.
Future Projections: Analysts project continued revenue growth, driven by increased sales of existing products and potential new product launches.
Recent Initiatives: Recent strategic initiatives include expanding the marketing and sales efforts for Trogarzo and EGRIFTA and pursuing partnerships to develop new therapies.
Summary
Theratechnologies is a growing biopharmaceutical company with approved products in HIV and oncology and a niche focus. It has strong financial control, growing revenues, and is focused on growing its commercial efforts to grow adoption. It faces significant competition, reliance on a few products, and potential pricing pressures that it must keep an eye on. Future success will depend on its ability to execute its growth strategy and develop new products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theratechnologies Inc.
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2016-01-04 | President, CEO & Director Mr. Paul Lévesque | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.theratech.com |
Full time employees - | Website https://www.theratech.com | ||
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.